Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Diagnostic imaging contrast agents with extended blood retention|
|Abstract:||The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.|
|Inventor(s):||McMurry; Thomas J. (Winchester, MA), Sijiki; Hironao (Gifu, JP), Scott; Daniel M. (Acton, MA), Lauffer; Randall B. (Brookline, MA)|
|Assignee:||Lantheus Medical Imaging, Inc. (North Billerica, MA)|
Patent Claim Types:|
see list of patent claims
Field: Medical technology
Back Citations: 106th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|8,017,105||September 13, 2015|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Israel||116847||<disabled in preview>|
|Hong Kong||1078468||<disabled in preview>|
|Hong Kong||1002551||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.